Reported Saturday, Teva Reports Patients With Tardive Dyskinesia Found AUSTEDO XR Easy To Take With Over 96% Agreement

Teva Pharmaceutical Industries Limited Sponsored ADR +0.43% Pre

Teva Pharmaceutical Industries Limited Sponsored ADR

TEVA

30.25

30.21

+0.43%

-0.13% Pre
  • Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) extended-release tablets
  • Patients reported high satisfaction (>89%) with AUSTEDO XR, with 96% expressing interest in continuing treatment
  • Almost all (>96%) patients relayed that AUSTEDO XR was easy to take
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.